.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AR14_DarunavirAndCobicistat.DarunavirAndCobicistat .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AR14_DarunavirAndCobicistat.DarunavirAndCobicistat| name: | DarunavirAndCobicistat | |
| ATC code: | J05AR14 | route: | oral |
| compartments: | 1 | |
| dosage: | 800 | mg |
| volume of distribution: | 1.46 | L |
| clearance: | 14.2 | L/h |
| other parameters in model implementation | ||
Darunavir and cobicistat is a fixed-dose combination antiretroviral medication used primarily for the treatment of HIV-1 infection in adults and adolescents. Darunavir is a protease inhibitor while cobicistat acts as a pharmacokinetic enhancer (booster) by inhibiting CYP3A-mediated metabolism, increasing serum concentrations of darunavir. This combination is approved for clinical use.
Pharmacokinetic parameters reported in healthy adult volunteers and HIV-infected patients; generally studied after oral administration of a fixed-dose tablet containing 800 mg darunavir and 150 mg cobicistat once daily.